IVF with Gestational Surrogacy: A Complete Guide for Intended Parents — Cost, Top Hospitals & Success Rates | MyMedicPlus

IVF with gestational surrogacy is an assisted reproductive technology (ART) pathway in which an embryo created through in vitro fertilisation is transferred to the uterus of a gestational carrier (surrogate) who carries the pregnancy to term on behalf of intended parents. The surrogate has no genetic relationship to the child — genetic material comes from the intended parents' eggs and sperm, or from one or two donors.

This pathway enables people to become biological parents when pregnancy in the intended mother is impossible or medically unsafe. It is the most effective fertility intervention available for these indications, with success rates per embryo transfer of 50–70% when quality-tested blastocysts are used.

The process integrates several medical components. Ovarian stimulation of the egg provider (intended mother or egg donor) using gonadotrophin injections produces multiple mature follicles. Eggs are retrieved transvaginally under sedation and fertilised in the laboratory with prepared sperm from the intended father or sperm donor. Resulting embryos are cultured to blastocyst stage (Day 5–6) and optionally undergo preimplantation genetic testing for aneuploidy (PGT-A) or monogenic disorders (PGT-M) before transfer. The highest-quality, chromosomally normal embryo is transferred to the prepared uterus of the surrogate, who has undergone endometrial preparation with oestrogen and progesterone.

Beyond the medical protocol, IVF surrogacy involves substantial legal, psychological, and ethical complexity. The legal status of surrogacy — altruistic versus commercial, the enforceability of surrogacy contracts, and the mechanism of legal parenthood transfer — varies dramatically between and within countries. Comprehensive medical, legal, and psychological screening of all parties is mandatory in ethical, regulated practice.

The process from initial consultation to birth typically spans 12–24 months, encompassing medical workup, matching with a surrogate, legal contracting, embryo creation, embryo transfer, and the pregnancy itself.

IVF with gestational surrogacy is indicated when pregnancy in the intended mother is impossible, consistently unsuccessful, or carries unacceptable medical risk to mother or child:

• Absent or Non-Functional Uterus: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome — congenital absence of the uterus and upper vagina — is an absolute indication for gestational surrogacy in women who wish to have genetically related children. Women who have undergone hysterectomy for cancer, fibroids, haemorrhage, or other indications similarly require a surrogate.
• Recurrent Implantation Failure (RIF): Women who have undergone multiple good-quality embryo transfers without successful implantation, despite thorough investigation, may benefit from gestational surrogacy if a uterine factor (thin endometrium, adenomyosis, fibroids, intrauterine adhesions) is identified or suspected as the likely barrier.
• Recurrent Pregnancy Loss (RPL): Women with three or more pregnancy losses attributable to uterine or immunological factors may be candidates for gestational surrogacy after thorough investigation and failure of established RPL treatments.
• Serious Maternal Medical Conditions: Women with severe cardiac disease (complex congenital heart disease, cardiomyopathy), renal or hepatic failure, uncontrolled severe autoimmune disease, or active malignancy in whom pregnancy poses a high risk of life-threatening maternal deterioration may carry their own genetic child via a surrogate.
• Cancer Treatment-Related Infertility: Women who have undergone pelvic radiotherapy causing uterine damage, or chemotherapy causing premature ovarian insufficiency (with cryopreserved embryos or donor eggs), may use a surrogate for family building.
• Same-Sex Male Couples: Gay male couples and single men require both donor eggs and a gestational surrogate to have genetically related children. This represents a growing proportion of intended parents in countries with supportive legal frameworks.

Both intended parents and the surrogate must meet strict medical, psychological, and legal eligibility criteria before an IVF surrogacy arrangement can commence.

Intended Parent Eligibility:

• A documented medical or clinical indication for surrogacy (see above) or legal eligibility under the relevant jurisdiction's surrogacy law
• Completion of fertility and genetic workup — semen analysis, ovarian reserve assessment (AMH, AFC), carrier genetic screening, karyotyping, and infectious disease screening
• Psychological evaluation assessing readiness, understanding of risks, and coping capacity
• Legal residency or citizenship requirements where applicable (e.g., India's Surrogacy Act 2021 restricts altruistic surrogacy to Indian married couples)

Surrogate Eligibility (ASRM/HFEA/ICMR Criteria):

• Age 21–40 years (ASRM recommends under 45 in exceptional cases; ICMR India requires age 25–35)
• Prior completion of her own family — she must have at least one living child of her own, confirming successful pregnancy and uterine receptivity
• BMI within 18–32 kg/m² (facility-dependent); obesity increases obstetric risk
• Non-smoker; no substance use; no serious mental health disorders
• Comprehensive psychological evaluation confirming genuine altruistic motivation, emotional stability, and a strong personal support network
• No criminal history; stable housing situation
• Full infectious disease and genetic screening: HIV, hepatitis B/C, syphilis, gonorrhoea, chlamydia, CMV status, rubella immunity, and blood group
• Uterine cavity assessment via saline infusion sonography (SIS) or hysteroscopy confirming no structural abnormalities

A surrogacy agreement — a detailed legal contract covering all financial, medical, parental rights, and contingency matters — is signed by all parties before any medical treatment commences. Independent legal representation for both the surrogate and intended parents is mandatory.

The IVF surrogacy process involves coordinated medical management of both the egg provider and the surrogate through several distinct phases:

• Own-Egg IVF (Intended Mother as Egg Provider): If the intended mother has adequate ovarian reserve, her eggs are used to create the embryos. Ovarian stimulation with gonadotrophin injections (FSH, LH) is monitored by serial ultrasound and oestradiol measurement. Egg collection is performed transvaginally under sedation. Laboratory fertilisation uses ICSI (intracytoplasmic sperm injection) for optimal fertilisation rates. Embryos are cultured to blastocyst (Day 5–6) stage.
• Donor Egg IVF: When the intended mother's egg quality is poor (diminished ovarian reserve, advanced maternal age, premature ovarian insufficiency, genetic carrier status), eggs from a young, screened anonymous or known donor are used. Donor egg cycles consistently achieve the highest success rates in IVF surrogacy (65–75% live birth per transfer in many centres) because donor eggs are sourced from young women with proven fertility.
• Preimplantation Genetic Testing (PGT-A and PGT-M): PGT-A tests embryos for chromosomal aneuploidy (abnormal chromosome number), the leading cause of IVF failure and miscarriage. PGT-M tests for single-gene disorders when one or both intended parents are carriers. Transferring only chromosomally normal, disease-free embryos substantially increases the probability of live birth per transfer and avoids transmission of genetic conditions.
• Frozen Embryo Transfer (FET): The standard protocol in IVF surrogacy. Embryos are cryopreserved after PGT-A biopsy, while legal and contractual preparations are completed. The surrogate undergoes endometrial preparation with oestradiol valerate (oral or patch) followed by progesterone supplementation (vaginal, intramuscular, or subcutaneous) to synchronise her uterine lining for embryo transfer.
• Fresh Embryo Transfer: Less commonly used, as it requires precise cycle synchronisation between egg provider and surrogate — logistically demanding and unnecessary when effective vitrification allows reliable embryo cryopreservation with equivalent or superior outcomes.

For couples and individuals for whom conventional IVF or natural conception is not an option, gestational surrogacy offers unique advantages that no other fertility pathway can replicate:

• Genetic Connection to Child: IVF gestational surrogacy allows at least one intended parent (or both) to have a genetic relationship to their child — an outcome not achievable through adoption. When the intended mother's eggs are used, both parents contribute genetic material. When donor eggs are used, the intended father retains genetic paternity.
• High Success Rates: With quality-screened blastocysts (particularly PGT-A tested embryos) and carefully selected surrogates with proven uterine receptivity, live birth rates per embryo transfer of 50–70% are achievable — higher than most other assisted reproduction pathways.
• No Genetic Tie Between Surrogate and Child: In gestational surrogacy, the surrogate is not genetically related to the child she carries. This eliminates a major source of legal uncertainty and emotional complexity, as the surrogate has no competing parental claim based on genetic maternity.
• Medically Safe for Surrogates: Surrogates are selected for prior successful uncomplicated pregnancies, optimising their safety. Obstetric monitoring and care are provided throughout the pregnancy by the surrogate's own obstetric team.
• Opens Parenthood to Previously Excluded Individuals: Gay male couples, single men, women with absolute uterine infertility, and women with life-threatening medical contraindications to pregnancy gain access to biological parenthood through a pathway that would otherwise be closed to them.
• Comprehensive Regulatory Frameworks: In well-regulated jurisdictions (US, UK, Canada, Greece), stringent medical, psychological, and legal safeguards protect the welfare of all parties — the surrogate, the intended parents, and the resulting child.

IVF gestational surrogacy carries medical, legal, psychological, and ethical risks that all parties must understand before proceeding:

• Legal Uncertainty: The legal status of surrogacy varies dramatically by country and can change with legislative reform. Arrangements made in jurisdictions with permissive laws may not be recognised in the intended parents' home country, creating complex nationality, citizenship, and legal parenthood disputes. International surrogacy carries particularly high legal risk.
• Surrogate's Health Risks: Pregnancy carries inherent obstetric risks for the surrogate — gestational diabetes, hypertension, pre-eclampsia, thromboembolism, and (rarely) maternal mortality. Ovarian hyperstimulation syndrome (OHSS) affects the egg provider during stimulation. Multiple pregnancies (from multiple embryo transfer) significantly amplify obstetric risk for surrogates.
• Exploitation Concerns: Commercial surrogacy raises serious ethical concerns about the potential exploitation of economically disadvantaged women. Several jurisdictions (India post-2021, Cambodia, Thailand, Nepal) have banned commercial surrogacy specifically because of documented exploitation. Ethical practice requires that surrogates be genuinely altruistically motivated and receive comprehensive legal, medical, and psychological support.
• Psychological Impact on Surrogate: While the majority of surrogates report positive experiences in prospective studies, a minority experience emotional difficulty relinquishing the baby at birth, particularly when unexpected attachment develops during pregnancy. Comprehensive pre-cycle psychological screening and post-partum psychological support are mandatory in ethical programmes.
• Treatment Failure: Despite optimal protocols, embryo transfers may fail due to implantation failure, early pregnancy loss, or chromosomal abnormalities. Multiple transfer attempts may be required, extending the emotional, financial, and time burden.
• Financial Risk: Surrogacy is expensive and largely not covered by health insurance. Total costs can reach $100,000–$180,000 in the US. Financial contracts may not cover all eventualities (e.g., surrogate's medical complications, multi-foetal pregnancy), creating unforeseen financial exposure.

After a successful embryo transfer and confirmed pregnancy, a comprehensive follow-up framework for both the surrogate and the intended parents is implemented:

Obstetric Monitoring of the Surrogate: Standard antenatal care is provided to the surrogate by her own obstetrician or midwife team. Intended parents are typically present at key appointments (12-week dating scan, 20-week anatomy scan) with the surrogate's consent. First-trimester combined screening and second-trimester anatomy ultrasound follow standard national protocols. For intended mothers with genetic risk factors, cell-free DNA (cfDNA / NIPT) testing or amniocentesis may be offered.

Progesterone Support: The surrogate continues luteal-phase progesterone supplementation (vaginal pessaries, intramuscular injections, or subcutaneous depot) until the placenta becomes autonomous — typically until 10–12 weeks gestation — to prevent early pregnancy loss in the absence of a corpus luteum.

Legal Parenthood Establishment: This is a critical parallel process:

• United States: Pre-birth orders are obtained from the family court in permissive states, establishing the intended parents as legal parents before birth. The birth certificate is issued in their names.
• United Kingdom: The intended parents apply for a Parental Order within 6 months of birth from the family court (Children Act 1989; HFEA 2008). The surrogate (and her spouse) consent to the order. The order permanently transfers all parental rights to the intended parents.
• India: Under the Surrogacy (Regulation) Act 2021, a birth certificate is issued in the names of the intended couple. A surrogacy board certificate must be obtained prior to the arrangement.

Post-Partum Psychological Support: Both the surrogate and the intended parents benefit from psychological debriefing and support after birth, navigating the emotional transition of baby handover and the beginning of the intended parents' independent family life.

IVF surrogacy is the most expensive fertility pathway globally. Costs vary substantially by country, chosen clinic, and whether the arrangement is altruistic or commercial:

• United States (Commercial/Compensated): The most expensive destination, with total all-inclusive costs typically ranging from $100,000 to $180,000 USD. This includes: surrogate compensation ($30,000–$55,000), IVF costs ($15,000–$30,000), legal fees ($15,000–$30,000), surrogate medical insurance, agency fees ($20,000–$30,000), psychological evaluation, screening, and contingency funds.
• United Kingdom (Altruistic): Surrogates receive 'reasonable expenses' only (no compensation), reducing costs significantly. IVF clinic costs, legal fees (Parental Order application), and surrogate expenses result in total costs of £30,000–£60,000 (approximately $38,000–$76,000). Matching through COTS (Childlessness Overcome Through Surrogacy) or other non-commercial organisations replaces US agency fees.
• India (Regulated Altruistic Post-2021): The Surrogacy (Regulation) Act 2021 restricts surrogacy to close relatives as gestational surrogates for Indian married heterosexual couples, eliminating the previously large commercial international market. Costs under the new regulated framework are substantially lower but access is restricted.
• Ukraine and Georgia (Commercial): These countries permit and legally support commercial surrogacy, including for international intended parents. Total costs range from $35,000–$60,000, making them significantly less expensive than the US, though intended parents face additional legal complexity integrating Ukrainian/Georgian birth certificates into their home country legal systems.
• Greece (Altruistic, Legally Regulated): Permits gestational surrogacy under court supervision for single women and heterosexual couples. A regulated, court-supervised framework with costs of approximately €30,000–€60,000.

For patients who cannot access IVF surrogacy, for whom it is legally prohibited, or who are seeking additional pathways to parenthood, the following alternatives should be considered:

• Adoption: Domestic or international adoption offers parenthood without genetic connection. In many countries, adoption processes are lengthy, involve extensive eligibility assessments, and domestic infant adoption is particularly competitive. International adoption is subject to complex bilateral agreements and is prohibited between some countries. Adoption does not provide a genetic relationship but offers legal permanence and parenthood of an existing child in need of a family.
• Embryo Donation (Embryo Adoption): Couples with surplus cryopreserved IVF embryos can donate them to other recipients. The recipient's uterus must be functional. For women who cannot carry a pregnancy but wish to avoid the legal complexity of surrogacy, embryo donation requires surrogacy as well — this alternative is only relevant for women with intact uterine function.
• Uterine Transplantation: An emerging experimental surgical procedure in which a uterus donated by a living or deceased donor is transplanted into a woman with uterine infertility. Published outcomes from Sweden (Gothenburg protocols), the United States, and India demonstrate successful pregnancies and live births post-transplantation. Uterine transplantation is not yet widely available and carries significant surgical risk (immunosuppression, graft rejection, surgical complications) but eliminates the need for a surrogate and preserves the intended mother's gestational role.
• Foster Care: Providing a temporary or long-term family home to children in the child welfare system. Not a pathway to legal parenthood by default, but may lead to adoption. Represents a meaningful alternative for those committed to caring for children already in need.
• Traditional Surrogacy: An older approach using the surrogate's own eggs. Legally more complex (the surrogate is the biological mother), ethically more ambiguous, and now rarely used by fertility specialists. Avoided in most regulated surrogacy programmes.